Molecular Profiling Expands Treatment Options in Pancreatic and Biliary Tract Cancers

Dina Ioffe, MD Fox Chase Cancer Center | Shubham Pant, MD, MBBS MD Anderson Cancer Center

January 19, 2026

Copy Link Share
Key Points

  • First-line treatment selection in pancreatic cancer is individualized, with FOLFIRINOX, NALIRIFOX, and gemcitabine plus nab-paclitaxel remaining reasonable options.

  • Neoadjuvant therapy strategies often require dose adjustments, altered schedules, and tailored treatment duration based on tolerance, response, and surgical considerations.

  • FGFR- and HER2–targeted agents are expanding therapeutic options in biliary tract cancer.

  • Advances in KRAS and pan-RAS–targeted therapies signal an optimistic future for pancreatic cancer.

At the 2026 ASCO Gastrointestinal (GI) Cancers Symposium, Dina Ioffe, MD, of Fox Chase Cancer Center, and Shubham Pant, MD, MBBS, of MD Anderson Cancer Center, discussed frontline and neoadjuvant treatment strategies for patients with pancreatic cancer, along with the expanding role of molecular profiling across GI malignancies.

They emphasized that regimen choice among FOLFIRINOX, NALIRIFOX, and gemcitabine plus nab-paclitaxel depends heavily on the patient’s Eastern Cooperative Oncology Group (ECOG) performance status and goals of care. While intensive regimens are appropriate for patients with good ECOG status, gemcitabine-based therapy remains an option, including for those with marginal performance status and for select patients with ECOG 0–1.

In neoadjuvant therapy, tolerability and hematologic toxicity, especially with weekly gemcitabine, often require dose reductions or schedule modifications. Dr. Pant explained that treatment duration is individualized, typically averaging 2 to 4 months before reassessment for surgery, rather than a fixed 6-month approach.

Drs. Ioffe and Pant expressed optimism about molecular profiling in biliary tract and pancreatic cancers. They described biliary tract cancer as a “target-rich” disease, highlighting actionable FGFR fusions and HER2 alterations. KRAS- and pan-RAS-targeted therapies are in development for pancreatic cancer, which are now widening the field, Dr. Pant said.